A detailed history of Great West Life Assurance CO transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Great West Life Assurance CO holds 8,830 shares of BEAM stock, worth $232,229. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,830
Previous 7,825 12.84%
Holding current value
$232,229
Previous $259,000 20.08%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$21.22 - $32.66 $21,326 - $32,823
1,005 Added 12.84%
8,830 $207,000
Q1 2024

May 13, 2024

BUY
$23.46 - $45.07 $9,290 - $17,847
396 Added 5.33%
7,825 $259,000
Q4 2023

Feb 13, 2024

BUY
$17.69 - $30.76 $18,379 - $31,959
1,039 Added 16.26%
7,429 $200,000
Q3 2023

Nov 14, 2023

BUY
$23.01 - $32.46 $69,030 - $97,380
3,000 Added 88.5%
6,390 $154,000
Q2 2023

Aug 10, 2023

BUY
$29.32 - $35.99 $5,893 - $7,233
201 Added 6.3%
3,390 $109,000
Q1 2023

May 12, 2023

SELL
$30.15 - $48.79 $7,386 - $11,953
-245 Reduced 7.13%
3,189 $98,000
Q4 2022

Feb 10, 2023

BUY
$36.73 - $51.6 $17,152 - $24,097
467 Added 15.74%
3,434 $136,000
Q3 2022

Nov 01, 2022

BUY
$39.79 - $70.31 $118,056 - $208,609
2,967 New
2,967 $142,000
Q2 2022

Aug 09, 2022

BUY
$29.86 - $62.36 $31,800 - $66,413
1,065 Added 58.26%
2,893 $112,000
Q1 2022

May 12, 2022

BUY
$53.73 - $82.16 $3,546 - $5,422
66 Added 3.75%
1,828 $112,000
Q4 2021

Feb 14, 2022

BUY
$68.02 - $99.06 $4,285 - $6,240
63 Added 3.71%
1,762 $140,000
Q2 2021

Aug 11, 2021

BUY
$64.12 - $128.71 $42,190 - $84,691
658 Added 63.21%
1,699 $218,000
Q1 2021

May 17, 2021

SELL
$71.28 - $120.75 $26,017 - $44,073
-365 Reduced 25.96%
1,041 $83,000
Q2 2020

Aug 17, 2020

BUY
$15.26 - $28.66 $21,455 - $40,295
1,406 New
1,406 $39,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.85B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Great West Life Assurance CO Portfolio

Follow Great West Life Assurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

News

Stay updated on Great West Life Assurance CO with notifications on news.